{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:20:46Z","timestamp":1790626846075,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.oret.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:11:32Z","timestamp":1786115492000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacologic Interventions for the Prevention and Treatment of Proliferative Vitreoretinopathy"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-3215","authenticated-orcid":false,"given":"Salem Abu","family":"Al-Burak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5132-8770","authenticated-orcid":false,"given":"Ameen","family":"Alizada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5644-861X","authenticated-orcid":false,"given":"Kareem","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelwahab","family":"Aleshawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Al-Dwairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-2188","authenticated-orcid":false,"given":"Hashem","family":"Abu Serhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2026.08.002_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.preteyeres.2015.07.005","article-title":"Proliferative vitreoretinopathy: a new concept of disease pathogenesis and practical consequences","volume":"51","author":"Pastor","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2026.08.002_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/IIO.0000000000000258","article-title":"Proliferative vitreoretinopathy: a review","volume":"59","author":"Idrees","year":"2019","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.oret.2026.08.002_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000438972","article-title":"Retinal detachment and proliferative vitreoretinopathy","volume":"55","author":"Kwon","year":"2015","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.preteyeres.2013.12.006","article-title":"Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?","volume":"40","author":"Pennock","year":"2014","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.oret.2026.08.002_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0161-6420(83)34588-7","article-title":"The classification of retinal detachment with proliferative vitreoretinopathy","volume":"90","year":"1983","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.08.002_bib6","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1001\/archopht.1992.01080180042027","article-title":"Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy","volume":"110","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0161-6420(01)00589-9","article-title":"Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial","volume":"108","author":"Asaria","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.08.002_bib8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0002-9394(98)00115-9","article-title":"Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group","volume":"126","author":"Wiedemann","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-79708-1","article-title":"Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial","volume":"14","author":"Nourinia","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2026.08.002_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2019-000293","article-title":"Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy","volume":"4","author":"Benner","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib11","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2147\/OPTH.S111893","article-title":"Intravitreal methotrexate infusion for proliferative vitreoretinopathy","volume":"10","author":"Sadaka","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib12","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2026.08.002_bib13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.51329\/mehdiophthal1522","article-title":"Ethical integrity in systematic reviews and meta-analyses: challenges, pitfalls, and best practices in ophthalmology","volume":"14","author":"Abukhaled","year":"2025","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib14","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2026.08.002_bib15","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2026.08.002_bib18","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.oret.2026.08.002_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.oret.2026.08.002_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2026.08.002_bib21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2026.08.002_bib22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.oret.2026.08.002_bib23","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.ophtha.2004.05.036","article-title":"A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy","volume":"111","author":"Charteris","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.08.002_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.sjopt.2014.03.005","article-title":"Efficacy of adjunctive 5-fluorouracil and low molecular weight heparin in patients undergoing vitrectomy for rhegmatogenous retinal detachment with high risk of proliferative vitreoretinopathy","volume":"28","author":"Ganekal","year":"2014","journal-title":"Saudi J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00417-004-0912-0","article-title":"A prospective, open-label, dose-escalating study of low molecular weight heparin during repeat vitrectomy for PVR and severe diabetic retinopathy","volume":"243","author":"Lane","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib26","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ophtha.2022.05.024","article-title":"Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial","volume":"129","author":"Schaub","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.08.002_bib27","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0181-5512(04)96264-X","article-title":"Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy","volume":"27","author":"Scheer","year":"2004","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib28","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ophtha.2006.08.042","article-title":"Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy","volume":"114","author":"Wickham","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.08.002_bib29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/BF00184858","article-title":"Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?","volume":"234","author":"Williams","year":"1996","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib30","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000533750","article-title":"Intravitreal injection of bevacizumab for the prevention of postoperative proliferative vitreoretinopathy in high-risk patients selected by laser flare photometry","volume":"246","author":"Gahon","year":"2023","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2026.08.002_bib31","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/eye.2014.21","article-title":"Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy","volume":"28","author":"Ghasemi Falavarjani","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2026.08.002_bib32","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1111\/j.1755-3768.2011.02108.x","article-title":"Intravitreal bevacizumab (Avastin) combined with vitrectomy for recurrences of proliferative vitreoretinopathy in von Hippel-Lindau disease","volume":"90","author":"Tano","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/2008-322X.188390","article-title":"Intravitreal injection of bevacizumab in primary vitrectomy to decrease the rate of retinal redetachment: a randomized pilot study","volume":"11","author":"Tousi","year":"2016","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.oret.2026.08.002_bib34","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/aos.12429","article-title":"Oral colchicine for prevention of proliferative vitreoretinopathy: a randomized clinical trial","volume":"93","author":"Ahmadieh","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib35","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ophtha.2008.05.016","article-title":"Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial","volume":"115","author":"Ahmadieh","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.08.002_bib36","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.01.021","article-title":"Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial","volume":"124","author":"Banerjee","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.08.002_bib37","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/IAE.0b013e3181fe5427","article-title":"Midterm results of low-dose intravitreal triamcinolone as adjunctive treatment for proliferative vitreoretinopathy","volume":"31","author":"Chen","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.08.002_bib38","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/bjo-2023-324318","article-title":"Early use of intravitreal triamcinolone to inhibit traumatic proliferative vitreoretinopathy: a randomised clinical trial","volume":"108","author":"Guo","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib39","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/IAE.0000000000004505","article-title":"The effect of steroids in the treatment of ocular hypotony associated with proliferative vitreoretinopathy","volume":"45","author":"Momenaei","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.08.002_bib40","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0008-4182(05)80052-3","article-title":"Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy","volume":"40","author":"Munir","year":"2005","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000351176","article-title":"Rhegmatogenous retinal detachment with high risk of proliferative vitreoretinopathy treated with episcleral surgery and an intravitreal dexamethasone implant","volume":"4","author":"Reibaldi","year":"2013","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib42","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1055\/s-0042-122384","article-title":"Intraocular dexamethasone implant as adjunct to silicone oil tamponade for proliferative vitreoretinopathy","volume":"234","author":"Sherif","year":"2017","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.oret.2026.08.002_bib43","first-page":"664","article-title":"Transoperative intravitreal dexamethasone implantation in patients with proliferative vitreoretinopathy","volume":"91","author":"Trenado-Luna","year":"2023","journal-title":"Cir"},{"key":"10.1016\/j.oret.2026.08.002_bib44","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/24741264241229262","article-title":"Effect of oral prednisone on the prevention and management of proliferative vitreoretinopathy after open-globe injury","volume":"8","author":"Yao","year":"2024","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.oret.2026.08.002_bib45","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1097\/IAE.0000000000004182","article-title":"Oral curcumin to reduce risk of proliferative vitreoretinopathy following rhegmatogenous retinal detachment repair","volume":"44","author":"Zheng","year":"2024","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.08.002_bib46","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1442-9071.2002.00554.x","article-title":"Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery","volume":"30","author":"Kumar","year":"2002","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0002-9394(87)90286-8","article-title":"Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy","volume":"104","author":"Wiedemann","year":"1987","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib48","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF00170548","article-title":"Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy","volume":"229","author":"Wiedemann","year":"1991","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib49","first-page":"632","article-title":"Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study","volume":"18","author":"Abdullatif","year":"2018","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.oret.2026.08.002_bib50","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.oret.2024.05.016","article-title":"Intravitreal infliximab for the treatment of proliferative vitreoretinopathy (FIXER): a randomized controlled phase II trial","volume":"8","author":"Younes","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.08.002_bib51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40942-025-00675-4","article-title":"A pilot study of intraoperative melphalan to prevent recurrent PVR: the IOMPVR study","volume":"11","author":"Moreira-Neto","year":"2025","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.oret.2026.08.002_bib52","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/futurepharmacol3020029","article-title":"Tolerability and efficacy of multiple series of intravitreal methotrexate injections for complex retinal detachment associated with proliferative vitreoretinopathy","volume":"3","author":"Ahmad","year":"2023","journal-title":"Future Pharmacol"},{"key":"10.1016\/j.oret.2026.08.002_bib53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/24741264221076357","article-title":"Systemic and intraocular methotrexate for the prevention and treatment of proliferative vitreoretinopathy in children with rhegmatogenous retinal detachment and underlying inflammatory disease","volume":"6","author":"Al-Moujahed","year":"2022","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.oret.2026.08.002_bib54","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/ICB.0000000000001252","article-title":"Rescue intravitreal methotrexate treatment following early recognition of proliferative vitreoretinopathy","volume":"17","author":"Alabi","year":"2023","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.oret.2026.08.002_bib55","doi-asserted-by":"crossref","DOI":"10.1097\/ICB.0000000000001910","article-title":"Regression of a subretinal proliferation band with intravitreal methotrexate in recurrent retinal detachment: a case report","author":"Alkhabaz","year":"2026","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.oret.2026.08.002_bib56","article-title":"Intraocular methotrexate for aggressive proliferative vitreoretinopathy in congenital aniridia","volume":"36","author":"Ambati","year":"2024","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.oret.2026.08.002_bib57","first-page":"47","article-title":"Intravitreal methotrexate infusion for proliferative vitreoretinopathy prophylaxis","volume":"11","author":"Aziz","year":"2022","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib58","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1159\/000526091","article-title":"Single-dose intravitreal methotrexate for recurrent retinal detachment with proliferative vitreoretinopathy","volume":"13","author":"Babel","year":"2022","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3928\/23258160-20250818-03","article-title":"Intravitreal methotrexate for the treatment and prevention of proliferative vitreoretinopathy in pediatric patients","volume":"56","author":"Bouaziz","year":"2025","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2026.08.002_bib60","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.oret.2024.10.023","article-title":"Association between systemic methotrexate therapy and proliferative vitreoretinopathy","volume":"9","author":"Chen","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.08.002_bib61","article-title":"Acupuncture-related globe penetration with post-traumatic proliferative vitreoretinopathy managed with adjunctive intravitreal methotrexate","volume":"19","author":"Denstedt","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.oret.2026.08.002_bib62","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3648134","article-title":"Anatomical and functional outcomes of intravitreal methotrexate infusion for proliferative vitreoretinopathy","volume":"2021","author":"El Baha","year":"2021","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib63","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/09273948.2019.1597894","article-title":"Intra-silicone oil injection of methotrexate in retinal reattachment surgery for proliferative vitreoretinopathy","volume":"28","author":"Falavarjani","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.oret.2026.08.002_bib64","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1097\/IAE.0000000000004181","article-title":"Intravitreal methotrexate injection for the treatment and prevention of proliferative vitreoretinopathy","volume":"44","author":"Hughes","year":"2024","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.08.002_bib65","article-title":"Use of intravitreal methotrexate infusion in complicated retinal detachment for prevention of proliferative vitreoretinopathy in a pilot study","volume":"13","author":"Jahangir","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.oret.2026.08.002_bib66","doi-asserted-by":"crossref","first-page":"666","DOI":"10.12669\/pjms.42.3.13344","article-title":"Comparison of per operative methotrexate infusion with postoperative intra silicon oil methotrexate injections for prevention of proliferative vitreoretinopathy development after vitrectomy for rhegmatogenous retinal detachment repair","volume":"42","author":"Jamil","year":"2026","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.oret.2026.08.002_bib67","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/24741264241249060","article-title":"Serial intravitreal methotrexate injections to combat recurrent proliferative vitreoretinopathy in a pediatric patient","volume":"8","author":"Jiao","year":"2024","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.oret.2026.08.002_bib68","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2024.10.006","article-title":"A modified intravitreal methotrexate protocol for the prevention of proliferative vitreoretinopathy after silicone oil removal","volume":"9","author":"Liu","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.08.002_bib69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000500271","article-title":"Repeated injection of methotrexate into silicone oil-filled eyes for grade C proliferative vitreoretinopathy","volume":"242","author":"Nourinia","year":"2019","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.oret.2026.08.002_bib70","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3928\/23258160-20250826-01","article-title":"Outcomes of complex PVR retinal detachment repair with and without intravitreal methotrexate at a single tertiary care center","volume":"57","author":"Ploumi","year":"2026","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2026.08.002_bib71","first-page":"387","article-title":"Intravitreal methotrexate as an adjuvant in vitrectomy in cases of retinal detachment with proliferative vitreoretinopathy","volume":"263","author":"Rajan","year":"2025","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib72","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1007\/s00417-021-05206-z","article-title":"Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy","volume":"259","author":"Roca","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib73","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/ICO.0000000000002774","article-title":"Corneal toxicity of intravitreal methotrexate used for the treatment of proliferative vitreoretinopathy in silicone oil-filled eyes: a case series","volume":"41","author":"Shen-Sampas","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.oret.2026.08.002_bib74","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40942-026-00856-9","article-title":"Prevention of postoperative proliferative vitreoretinopathy in complex retinal detachments with serial intravitreal methotrexate injections","volume":"12","author":"Soares","year":"2026","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.oret.2026.08.002_bib75","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3928\/23258160-20230220-01","article-title":"Low-dose intravitreal methotrexate for proliferative vitreoretinopathy","volume":"54","author":"Ullah","year":"2023","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2026.08.002_bib76","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3928\/23258160-20260413-01","article-title":"The role of systemic methotrexate on preventing proliferative vitreoretinopathy following retinal detachment repair","volume":"57","author":"Yavari","year":"2026","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2026.08.002_bib77","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1097\/IAE.0000000000004602","article-title":"Real-world efficacy of intravitreal methotrexate for managing proliferative vitreoretinopathy in recurrent rhegmatogenous retinal detachment","volume":"45","author":"Yun","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.oret.2026.08.002_bib78","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41433-019-0408-0","article-title":"Intraocular application of mitomycin C to prevent proliferative vitreoretinopathy in perforating and severe intraocular foreign body injuries","volume":"33","author":"Assi","year":"2019","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2026.08.002_bib79","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1177\/1120672120976038","article-title":"A modified application of intraocular mitomycin C to prevent proliferative vitreoretinopathy in perforating and severe eye injuries","volume":"31","author":"G\u00fcrelik","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib80","doi-asserted-by":"crossref","DOI":"10.1155\/joph\/9927416","article-title":"Effect of adjuvant mitomycin-C on recurrent rhegmatogenous retinal detachment with proliferative vitreoretinopathy managed by relaxing retinotomy and retinectomy","volume":"2025","author":"G\u00fcrelik","year":"2025","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib81","doi-asserted-by":"crossref","DOI":"10.1177\/24741264261445237","article-title":"Outcomes of primary rhegmatogenous retinal detachment repair with adjunctive mitomycin C","author":"Shaheen","year":"2026","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.oret.2026.08.002_bib82","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ajo.2008.05.002","article-title":"Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy","volume":"146","author":"Chang","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib83","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0161-6420(95)31007-X","article-title":"The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy","volume":"102","author":"Fekrat","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2026.08.002_bib84","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/bjophthalmol-2018-312839","article-title":"Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial","volume":"103","author":"London","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib85","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archopht.125.9.1161","article-title":"Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy","volume":"125","author":"Schiff","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib86","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/jamaophthalmol.2025.2497","article-title":"Mammalian target of rapamycin inhibition as a therapeutic target for prevention of proliferative vitreoretinopathy","volume":"143","author":"Alsoudi","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib100","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12886-022-02449-0","article-title":"Evaluation of Ab externo subretinal bands removal during pars plana vitrectomy for rhegmatogenous retinal detachment complicated by proliferative vitreoretinopathy","volume":"22","author":"Elbaha","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib87","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40942-025-00680-7","article-title":"Incidence and risk factors for recurrence after surgical treatment of rhegmatogenous retinal detachment: a retrospective cohort study","volume":"11","author":"Tawfik","year":"2025","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.oret.2026.08.002_bib88","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41433-025-03846-7","article-title":"Non-surgical interventions for proliferative vitreoretinopathy: a systematic review","volume":"39","author":"Hunter","year":"2025","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2026.08.002_bib89","first-page":"1393","article-title":"Steroids as an adjunct for reducing the incidence of proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery: a systematic review and meta-analysis","volume":"9","author":"Shi","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.oret.2026.08.002_bib90","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00417-010-1389-7","article-title":"Safety and feasibility of a novel intravitreal tamponade using a silicone oil\/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study","volume":"248","author":"Kralinger","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib91","doi-asserted-by":"crossref","DOI":"10.2147\/OPTH.S579707","article-title":"The effect of statins on the prevention of proliferative vitreoretinopathy (PVR) following vitrectomy or scleral buckling for rhegmatogenous retinal detachment (RRD): a pilot randomized controlled trial","volume":"20","author":"Gordiz","year":"2026","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib92","first-page":"894","article-title":"Adalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organotypic culture of porcine neuroretina","volume":"19","author":"Fernandez-Bueno","year":"2013","journal-title":"Mol Vis"},{"key":"10.1016\/j.oret.2026.08.002_bib93","article-title":"Effect of adalimumab as an anti-inflammatory agent on gene expression of retinal pigment epithelial cells","volume":"174","author":"Nowroozzadeh","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.oret.2026.08.002_bib94","first-page":"1725","article-title":"Effects of resveratrol on ARPE-19 cell proliferation and migration via regulating the expression of proliferating cell nuclear antigen, P21, P27 and p38MAPK\/MMP-9","volume":"9","author":"Hao","year":"2016","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib95","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41598-025-85882-7","article-title":"Hirudo extract ameliorates proliferative vitreoretinopathy by promoting autophagy and attenuating the THBS2\/PI3K\/Akt pathway","volume":"15","author":"Huang","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.oret.2026.08.002_bib96","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.survophthal.2025.03.008","article-title":"Exploring the potential of rho kinase inhibitors in ophthalmology: from mechanisms to clinical practice","volume":"70","author":"Tan","year":"2025","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib97","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0002-9394(01)01423-4","article-title":"A cost-utility analysis of interventions for severe proliferative vitreoretinopathy","volume":"133","author":"Brown","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib98","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0039-6257(98)00023-X","article-title":"Proliferative vitreoretinopathy: an overview","volume":"43","author":"Pastor","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2026.08.002_bib99","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1136\/bjo.79.10.953","article-title":"Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment","volume":"79","author":"Charteris","year":"1995","journal-title":"Br J Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302600391X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302600391X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:52:12Z","timestamp":1790369532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246865302600391X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":98,"alternative-id":["S246865302600391X"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.08.002","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Interventions for the Prevention and Treatment of Proliferative Vitreoretinopathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}